Healthy donors get drug to supercharge immune cells
NCT ID NCT06040918
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early study tested a drug called N-803 in 10 healthy volunteers to see if it could help collect and grow more natural killer cells from their blood. The main goal was to check safety and side effects. The study is already complete, but it does not test whether these cells can fight any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chan Soon-Shiong Institute for Medicine
El Segundo, California, 90245, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
N-803 (a drug given as a shot under the skin)
What this could lead to
If successful, this could help improve methods for collecting and growing natural killer cells for future therapies.
What could go wrong
This is a very early, small study in healthy people, not patients. It only looks at safety and cell collection, not whether the cells can treat any disease.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.